Zhejiang Kang De Pharma Group Co., Ltd. romanized
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference caf8f32aed
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/13 06:42.
Drug filings
12 acceptance records as first applicant, grouped into 12 source drug names. Source data as of 2026/11/13 06:42.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
参百宁神口服液 · No verified English name 1 records · Latest accepted 2026/10/12
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2605111 | Supplement | 2026/10/12 | Zhejiang Kang De Pharma Group Co., Ltd. romanized | CDE ↗ |
保胎灵片 · No verified English name 1 records · Latest accepted 2026/07/30
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2603757 | Supplement | 2026/07/30 | Zhejiang Kang De Pharma Group Co., Ltd. romanized | CDE ↗ |
比拉斯汀口崩片 · No verified English name 1 records · Latest accepted 2026/05/13
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2601114 | Generic | 2026/05/13 | Zhejiang Kang De Pharma Group Co., Ltd. romanized | CDE ↗ |
Ezetimibe and Atorvastatin Calcium Tablets(II) 1 records · Latest accepted 2026/04/15
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2600866 | Generic | 2026/04/15 | Zhejiang Kang De Pharma Group Co., Ltd. romanized | CDE ↗ |
Azithromycin for Suspension 1 records · Latest accepted 2025/10/16
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2550339 | Supplement | 2025/10/16 | Zhejiang Kang De Pharma Group Co., Ltd. romanized | CDE ↗ |
Gliclazide Modified Release Tablets 1 records · Latest accepted 2025/09/10
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2550321 | Supplement | 2025/09/10 | Zhejiang Kang De Pharma Group Co., Ltd. romanized | CDE ↗ |
红花逍遥片 · No verified English name 1 records · Latest accepted 2024/09/25
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2401809 | Supplement | 2024/09/25 | Zhejiang Kang De Pharma Group Co., Ltd. romanized | CDE ↗ |
妇必舒阴道泡腾片 · No verified English name 1 records · Latest accepted 2024/05/21
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2400860 | Supplement | 2024/05/21 | Zhejiang Kang De Pharma Group Co., Ltd. romanized | CDE ↗ |
口炎清片 · No verified English name 1 records · Latest accepted 2024/05/14
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2400826 | Supplement | 2024/05/14 | Zhejiang Kang De Pharma Group Co., Ltd. romanized | CDE ↗ |
热淋清片 · No verified English name 1 records · Latest accepted 2024/05/14
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2400827 | Supplement | 2024/05/14 | Zhejiang Kang De Pharma Group Co., Ltd. romanized | CDE ↗ |
珍芪补血口服液 · No verified English name 1 records · Latest accepted 2024/05/14
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2400825 | Supplement | 2024/05/14 | Zhejiang Kang De Pharma Group Co., Ltd. romanized | CDE ↗ |
丹龙口服液 · No verified English name 1 records · Latest accepted 2024/01/10
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2400041 | Supplement | 2024/01/10 | Zhejiang Kang De Pharma Group Co., Ltd. romanized | CDE ↗ |
Changes in the last 90 days
5 events from 2026/08/16 to 2026/11/13. CDE data as of 2026/11/13 06:42; NMPA data as of 2026/11/12 18:32.
This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Accepted: 1 applicationNo longer listed under review: 2 applicationsSupplement delivery: 2 applications
- 2026/11/06No longer listed under review
保胎灵片 · No verified English name
CYZB2603757
Fact date: 2026/11/06 · Site observation date: 2026/11/06
Accepted: 2026/07/30
not on the CDE under-review list in this snapshot; NMPA published approval-document delivery for this acceptance number on 2026/11/06 (approval no.: —; approval date: 2026/11/04); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 80
NMPA · Table row 80 ↗ View source ↗ - 2026/11/04Supplement delivery
保胎灵片 · No verified English name
CYZB2603757
Fact date: 2026/11/04 · Publication date: 2026/11/06 · Site observation date: 2026/11/06
Supplemental application; excluded from new marketing approvals.
View source · Table row 80 ↗ - 2026/11/04No longer listed under review
Azithromycin for Suspension
CYHB2550339
Fact date: 2026/11/04 · Site observation date: 2026/11/04
Accepted: 2025/10/16
not on the CDE under-review list in this snapshot; NMPA published approval-document delivery for this acceptance number on 2026/11/03 (approval no.: —; approval date: 2026/11/02); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 3
NMPA · Table row 3 ↗ View source ↗ - 2026/11/02Supplement delivery
Azithromycin for Suspension
CYHB2550339
Fact date: 2026/11/02 · Publication date: 2026/11/03 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 3 ↗ - 2026/10/12Accepted
参百宁神口服液 · No verified English name
CYZB2605111
Fact date: 2026/10/12 · Site observation date: 2026/10/22
View source ↗
Under review
3 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/13 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| 参百宁神口服液 · No verified English name | CYZB2605111 | Supplement | 2026/10/12 | Zhejiang Kang De Pharma Group Co., Ltd. romanized | CDE ↗ |
| 比拉斯汀口崩片 · No verified English name | CYHS2601114 | Generic | 2026/05/13 | Zhejiang Kang De Pharma Group Co., Ltd. romanized | CDE ↗ |
| Ezetimibe and Atorvastatin Calcium Tablets(II) | CYHS2600866 | Generic | 2026/04/15 | Zhejiang Kang De Pharma Group Co., Ltd. romanized | CDE ↗ |
Catalogue holder records
2 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/13 06:39. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | Approval number | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Gliclazide Modified Release Tablets | Zhejiang Kang De Pharma Group Co., Ltd. romanized | Zhejiang Kang De Pharma Group Co., Ltd. romanized | 国药准字H20093374 | 2026/09/02 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Azithromycin for Suspension | Zhejiang Kang De Pharma Group Co., Ltd. romanized | Zhejiang Kang De Pharma Group Co., Ltd. romanized | 国药准字H20066930 | 2026/11/02 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
0 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/13 06:41.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | |||||
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
0 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/13 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | |||||
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/13 06:42
- Chemical-drug catalogue
- Last successful update: 2026/11/13 06:39
- Full API register
- Last successful update: 2026/11/13 06:41
- NMPA drug delivery notices
- Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete
First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.